Utilizing generative AI for drug discovery in the cloud

Evozyne is a biotechnology startup based in Chicago that combines deep learning and the principles of evolution to design novel protein therapeutics. Evozyne will discuss the development of a generative AI model built on NVIDIA’s BioNeMo platform running on AWS to create two new proteins with supernatural function and potential in therapeutics and sustainability. The developed large language models (LLMs) outperform traditional protein engineering approaches, such as directed evolution, by enabling the production of functional synthetic molecules with hundreds of mutations in a single round. In this webinar, the essential role of large, pre-trained models and libraries provided by BioNeMo to unlock such generative design will be reviewed, as well as the benefits cloud computing has provided in storage, automation, and parallelization over on-premises options.